Date of Document: February 24, 2021
CURRICULUM VITAE

John Paul Scott MD
Professor
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics

OFFICE ADDRESS:
The Blood Center
P O Box 2178
Milwaukee, WI 53201

EDUCATION:
1966 - 1970 B.S. Cum Laude, University of Notre Dame, Notre Dame, IN
1970 - 1974 M.D. Cum Laude, Loyola University Stritch School of Medicine, Chicago, IL

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1974 - 1977 Pediatric Resident, University of Colorado Medical Center
1977 - 1979 Pediatric Hematology-Oncology Fellow, University of Colorado Medical Center

FACULTY APPOINTMENTS:
1979 - 1980 Instructor of Pediatrics, Loyola University Stritch School of Medicine, Chicago, IL
1980 - 1986 Assistant Professor of Pediatrics, Northwestern University Medical School, Chicago, IL
1986 - 1987 Associate Professor of Pediatrics, Northwestern University Medical School, Chicago, IL
1987 - 1989 Associate Clinical Professor of Pediatrics, The Medical College of Wisconsin, Milwaukee, WI
1987 - 2015 Investigator, Hemostasis Research Section, Blood Center of Wisconsin, Milwaukee, WI
1989 - 1995 Associate Professor of Pediatrics, Medical College of Wisconsin, Milwaukee, WI
1994 - 1995 Associate Professor of Pathology, Medical College of Wisconsin, Milwaukee, WI
1995 - Present Professor of Pediatrics, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
1979 - 1980 Attending Hematologist, Loyola University Medical Center, Chicago, IL
1980 - 1987 Director, Hemophilia Center, Children's Memorial Hospital, Chicago, IL
1980 - 1987 Attending Hemtologist, Children's Memorial Hospital, Chicago, IL
1980 - 1987 Director, Special Coagulation Laboratory, Children's Memorial Hospital, Chicago, IL
1987 - Present Attending Hematologist, Children's Hospital of Wisconsin, Milwaukee, WI
1989 - Present Medical Director, Wisconsin Sickle Cell Center, Children's Hospital of Wisconsin, Milwaukee, WI
1990 - 2005 Director, Pediatric Hematology/Oncology/BMT Fellowship Training Program, Medical College of Wisconsin, Milwaukee, WI
1993 - 2000 Chief, Department of Hematology/Oncology/BMT, Children's Hospital of Wisconsin, Milwaukee, WI
2008 - 2012 Co-leader, Pediatric Hematology/Oncology/BMT Leadership Group, Medical College of Wisconsin, Milwaukee, WI
2008 - Present Supervisor, Clinical Hematology, Medical College of Wisconsin, Milwaukee, WI
2008 - Present Supervisor, Two Nurse Practitioners Hematology, Children's Hospital of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Pediatrics
1980
None
Pediatric Hematology/Oncology
1982
None
 
Licensure
Number Issue DateExpiration
Wisconsin Medical License
28431-20
06/19/1987
10/31/2017
 

AWARDS AND HONORS:
1972 Alpha Omega Alpha
1983 Teacher of the Year, Children's Memorial Hospital, Northwestern Medical School, Department of Pediatrics
1998 Outstanding Teacher of the Year, Children's Hospital of Wisconsin, Department of Pediatrics, Medical College of Wisconsin
2002 Outstanding teacher of the Year, Children's Hospital of Wisconsin, Department of Pediatrics, Medical College of Wisconsin
2007 - 2008 David A Lewis, MD, Outstanding Advisor Award, Department of Pediatrics, Medical College of Wisconsin

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
1979 - Present Chicago Medical Society
1979 - 1987 Executive Board, Hemophilia Foundation of Illinois
1980 - Present American Heart Association: Council on Thrombosis
1984 - Present Chairman, Medical Advisory Council, Hemophilia Foundation of Illinois
1985 - Present American Society of Hematology (ASH)
1985 - Present American Federation for Clinical Research (AFCR)
1985 - Present International Society on Thrombosis and Hemostasis
1986 - Present American Association for the Advancement of Sciences (AAAS)
1988 - Present Society for Pediatric Research (SPR)
2000 - Present American Society of Pediatric Hematology Oncology (ASPHO)
2000 - Present Public Responsibility in Medicine and Research (PRIM&R)
2000 - Present The Applied Research Ethics National Association (ARENA)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
American Journal of Pediatric Hematology-Oncology
Journal of Clinical Investigation
Blood
New England Journal of Medicine
Journal of Pediatrics
American Journal of Hematology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1989 - Present Chairman, Hemoglobinopathy Subcommittee
1989 - Present Member, Umbrella Committee, State of Wisconsin Newborn Screening
2000 - Present Ad Hoc Member, IRB 1-6, Member Promotions Committee, Medical College of Wisconsin, Department of Pediatrics
2000 - Present Chairman, Human Research Review Board (IRB) #1, Children's Hospital of Wisconsin, Milwaukee, WI
2000 - Present Member,, Human Research Review Board (IRB #2), Children's Hospital of Wisconsin, Milwaukee, WI

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis (MAGIC) 5RO1HD062347
Source:
NIH
Role:
Co-Investigator
Dates:
2010 - 2014
 
Title:
Wisconsin Sickle Cell Disease Comprehensive Center
Source:
State of WI Newborn Screening Program
Role:
Principal Investigator
Dates:
07/01/2012 - 06/30/2014
Direct Funds:
$322,990
 
Prior
Peer Review
Title:
Red blood cell adhesion in sickle cell disease RO-HL70981-01
Source:
NIH/NHLBI
Role:
Co-Investigator
Dates:
07/01/2002 - 05/31/2006
Direct Funds:
$731,000
 
Title:
Mechanisms of vaso-occlusion in sickle cell disease: role of coagulation and inflammatory RO-HL044612
Source:
NIH/NHLBI
Role:
Co-Investigator
Dates:
05/01/2005 - 04/30/2010
 
Title:
Switch Trial Stroke with Transfusions Changing to Hydroxyurea (SWITCH) 1 UO1 HL078787-0141
Source:
NHLBI/INIH
Role:
PI
Dates:
2005 - 2010
 
Title:
Midwest Basic and Translational Research Program (BTRP) U54 HL090503
Source:
NIH/NH LBI
Role:
Co-Investigator
Dates:
06/15/2008 - 03/31/2012
 
Title:
Arginine Supplementation in Sickle Cell Anemia: Physiological and Prophylactic Effects
Source:
NHLBI
Role:
PI
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
"A User's Guide to Coagulation Testing", 29th Annual Winter Refresher Course for Family Physicians, Waukesha, WI, 01/28/1999
"Hematology", Ace the Boards - American Board of Pediatrics Examination Course Review, sponsored by the Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 09/20/2000
"You, Me, and the IRB", Pediatric Academic Conference, Medical College of Wisconsin, Milwaukee, WI, 09/29/2000
"Informed Consent", Invited Lecture, Froedtert Memorial Lutheran Hospital, Milwaukee, WI, 11/02/2000
"You, Me, and the IRB", IRB Presentation to Critical Care Fellows and Faculty, Children's Hospital of Wisconsin, Milwaukee, WI, 09/24/2001
"Hematology", Ace the Boards - American Board of Pediatrics Examination Course Review, Medical College of Wisconsin, Milwaukee, WI, 09/28/2001
"Science, Ethics, $$$ - The IRB Hot Seat", Pediatric Academic Conference, Medical College of Wisconsin, Milwaukee, WI, 10/05/2001
"Banking Genetic Materials", Midwest Ethics Committee Network's 4th Annual Course for Health Care Psychologists Program, Medical College of Wisconsin, Milwaukee, WI, 11/19/2001
"Sickle Cell Management", Grand Rounds, St. Michael Hospital, Milwaukee, WI, 06/06/2002 - 06/06/2001
"Hemoglobin and Hemoglobinopathies", Blood Banking/Transfusion Medicine Lecture Series, The Blood Center of Southeastern Wisconsin, Milwaukee, WI, 08/22/2002
"Thoughtful Inclusion of Children in Research of Vulnerable Participants", Human Research Protection: Striving for Excellence, The Medical College of Wisconsin, Milwaukee, WI, 06/02/2005
 
Regional
"Hematology for the Practitioner", American Academy of Pediatrics 1999 Spring Session, Chicago, IL, 04/17/1999
"Recent Advances in the Treatment of ITP", Invited Lecture, University of Michigan, Ann Arbor, MI, 06/02/1999
"Diagnostic Approach to Anemia", Grand Rounds, St. Therese Hospital, Waukegan, IL, 04/14/2000
"Sickle Cell Anemia", Continuing Medical Education Activity, All Saints Healthcare System Inc.Saint Mary's Medical Center, Racine, WI, 06/29/2000
"Sickle Cell", Continuing Medical Education Activity, All Saints - St. Mary's Medical Center, Racine, WI, 07/31/2002
"Thrombotic Disorders", The Pediatric Hematology/Oncology Board Review Course, Sponsored by the American Society of Pediatric Hematology/Oncology, Northbrook, IL, 09/27/2002
 

COMMITTEE SERVICE:
Medical College of Wisconsin
2008 - Present Ad hoc member, IRB 1-6, Medical College of Wisconsin
 
Hospital
1991 - 2003 Member, Blood Utilization Committee, Children's Hospital of Wisconsin
1993 - 2008 Member, Patient Care Committee, Children's Hospital of Wisconsin
2000 - 2008 Chairman, IRB, Children's Hospital of Wisconsin
2008 Member, Member, IRB #2, Children's Hospital of Wisconsin
2008 - Present Chairman, IRB #1, Children's Hospital of Wisconsin
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
1989 - 2001 Pediatric ward attending physician,1 month annually with supervision of 5-6 MCW third year students.
1989 - 2001 Sickle Cell Disease Lectures given to MCW junior pediatric students every 8 weeks.
2013 MS-2 Discovery Curriculum: Hemoglobinopathy lecture
2013 MS-1 Biochemistry: Sickle Cell Disease, Group Leader
2013 MS-2 Discovery Curriculum: Thrombosis, Group Leader
2013 MS-2 Discovery Curriculum: Hemostasis Bleeding Disorders, Group Leader
2014 MS-2 Discovery Curriculum: Hemoglobinopathy lecture, Hemostasis/Bleeding disorders: small group leader, Thrombosis: small group leader
2014 MS-1 Biochemistry: Sickle Cell Disease, small group leader
 
Postdoctoral Fellow Education
1990 Developed and wrote application for accreditation of Pediatric Hematology/ Oncology fellowship program approved by ACGME.
1998 Wrote renewal application for accreditation of Pediatric Hematology/Oncology fellowship program approved by ACGME for full 5 year accreditation.
2005 Wrote renewal application for accreditation of Pediatric Hematology/Oncology fellowship program approved by ACGME for full 5 year accreditation.
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
Kara Kassay, Medical College of Wisconsin, 06/1993 - 09/1993 Mentor - MS-1 Lab Preceptorship
 
Clinical/Research Fellows
Ranier Gedeit, MD, Medical College of Wisconsin, 1991 - 1993 Mentor - Endothelial Cell Biology Lab
Liza Thiel, MD, Medical College of Wisconsin, 2008 - 2010 Mentor
 
Faculty
Cheryl Hillery, MD, Medical College of Wisconsin, 2006 Support in promotion to Professor
Julie Panepinto, MD, Medical College of Wisconsin, 2006 Support in promotion to Associate Professor
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Scott JP, Montgomery RR, Tubergen DG, Hays T. Acquired von Willebrand's disease in association with Wilm's tumor: regression following treatment. Blood. 1981 Oct;58(4):665-9.
2. Scott JP, Montgomery RR. Platelet von Willebrand's antigen II: active release by aggregating agents and a marker of platelet release reaction in vivo. Blood. 1981 Dec;58(6):1075-80.
3. Scott JP, Schiff DW, Githens JH. The autoerythrocyte sensitization syndrome as the primary manifestation of systemic lupus erythematosus. J Pediatr. 1981 Oct;99(4):598-600.
4. Loren AB, Maggi JC, Scott JP, Anderson CL, Niwa Y, Yokoyama MM. Evaluation of neonatal neutrophil function using the combined immunobead/NBT dye reduction assay. J Clin Lab Immunol. 1982 Jan;7(1):71-4.
5. Maggi JC, Angelats J, Scott JP. Gangrene in a neonate following dopamine therapy. J Pediatr. 1982 Feb;100(2):323-5.
6. Delaplane D, Scott JP, Riggs TW, Silverman BL, Hunt CE. Urokinase therapy for a catheter-related right atrial thrombus. J Pediatr. 1982 Jan;100(1):149-52.
7. Scott JP, Morgan E. Coagulopathy of disseminated neuroblastoma. J Pediatr. 1983 Aug;103(2):219-22.
8. McLeod BC, Scott JP. Use of 'single donor' factor VIII from plasma exchange donation. JAMA. 1984 Nov 16;252(19):2726-9.
9. Scott JP, Gerber P, Maryjowski MC, Pachman LM. Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis. Arthritis Rheum. 1985 Mar;28(3):256-61.
10. Scott JP, Maurer HS, Dias L. Septic arthritis in two teenaged hemophiliacs. J Pediatr. 1985 Nov;107(5):748-51.
11. Vailas GN, Brouillette RT, Scott JP, Shkolnik A, Conway J, Wiringa K. Neonatal aortic thrombosis: recent experience. J Pediatr. 1986 Jul;109(1):101-8.
12. Lloyd-Still JD, Scott JP, Crussi F. The spectrum of Epstein-Barr virus hepatitis in children. Pediatr Pathol. 1986;5(3-4):337-51.
13. Green D, Scott JP. Is sickle cell crisis a thrombotic event? Am J Hematol. 1986 Dec;23(4):317-21.
14. McLeod BC, Sassetti RJ, Cole ER, Scott JP. A high-potency, single-donor cryoprecipitate of known factor VIII content dispensed in vials. Ann Intern Med. 1987 Jan;106(1):35-40.
15. Bontempo FA, Lewis JH, Gorenc TJ, Spero JA, Ragni MV, Scott JP, Starzl TE. Liver transplantation in hemophilia A. Blood. 1987 Jun;69(6):1721-4. PMCID: PMC2965591
16. Scott JP, Arroyave C. Activation of complement and coagulation in juvenile dermatomyositis. Arthritis Rheum. 1987 May;30(5):572-6.
17. McLeod BC, Sassetti RJ, Cole ER, Scott JP. Long-term frequent plasma exchange donation of cryoprecipitate. Transfusion. 1988 Jul-Aug;28(4):307-10.
18. McLeod BC, Sassetti RJ, Owens EA, Scott JP. Simultaneous collection of platelets and cryoprecipitate by plasma-exchange donation. Transfusion. 1989 May;29(4):332-6.
19. Reddy SV, Zhou ZQ, Rao KJ, Scott JP, Watzke H, High KA, Jagadeeswaran P. Molecular characterization of human factor XSan Antonio. Blood. 1989 Oct;74(5):1486-90.
20. McLeod BC, Scott JP. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII. Prog Clin Biol Res. 1990;324:189-98.
21. Rao KJ, Lyman G, Hamsbhushanam K, Scott JP, Jagadeeswaran P. Human factor IXLincoln Park: a molecular characterization. Mol Cell Probes. 1990 Oct;4(5):335-40.
22. McLeod BC, Sassetti RJ, Cole ER, Scott JP. Platelet collection during plasma exchange donation of cryoprecipitate. Prog Clin Biol Res. 1990;337:481-3.
23. Kunicki TJ, Furihata K, Kekomaki R, Scott JP, Nugent DJ. A human monoclonal autoantibody specific for human platelet glycoprotein IIb (integrin alpha IIb) heavy chain. Hum Antibodies Hybridomas. 1990;1(2):83-95.
24. Schmidt ML, Smith HE, Gamerman S, DiMichele D, Glazer S, Scott JP. Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor. Br J Haematol. 1991 Jul;78(3):460-3.
25. Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem. 1991 Oct 15;266(29):19146-9.
26. Scott JP, Montgomery RR, Retzinger GS. Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. J Biol Chem. 1991 May 05;266(13):8149-55.
27. Scott JP, Montgomery RR. The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the "neutral" monoclonal antibody binding assay. Am J Clin Pathol. 1991 Dec;96(6):723-8.
28. Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets. Blood. 1992 Apr 15;79(8):2048-55.
29. O'Hair DP, McManus RP, Johnson CP, Scott JP. The role of antiendothelial antibody in primate cardiac xenograft rejection. Transplant Proc. 1992 Apr;24(2):506-7.
30. Rackoff WR, Ohene-Frempong K, Month S, Scott JP, Neahring B, Cohen AR. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr. 1992 Jun;120(6):882-5.
31. Potter C, Gill JC, Scott JP, McFarland JG. Heparin-induced thrombocytopenia in a child. J Pediatr. 1992 Jul;121(1):135-8.
32. McManus RP, O'Hair DP, Komorowski R, Scott JP. Immunosuppressant combinations in primate cardiac xenografts. A review. Ann N Y Acad Sci. 1993 Nov 30;696:281-4.
33. Scott JP, Montgomery RR. Therapy of von Willebrand disease. Semin Thromb Hemost. 1993;19(1):37-47.
34. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol. 1994 Sep;47(1):36-40.
35. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994 Jan;93(1):81-8. PMCID: PMC293737
36. Hillery CA, Du MC, Montgomery RR, Scott JP. Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood. 1996 Jun 01;87(11):4879-86.
37. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996 Jun;128(6):820-8.
38. Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, Davies SC, Ohene-Frempong K, Bernaudin F, Matthews DC, Storb R, Sullivan KM. Bone marrow transplantation for sickle cell disease. N Engl J Med. 1996 Aug 08;335(6):369-76.
39. Werlin SL, Scott JP. Is biliary sludge a stone-in-waiting? J Pediatr. 1996 Sep;129(3):321-2.
40. Walters MC, Patience M, Leisenring W, Eckman JR, Buchanan GR, Rogers ZR, Olivieri NE, Vichinsky E, Davies SC, Mentzer WC, Powars D, Scott JP, Bernaudin F, Ohene-Frempong K, Darbyshire PJ, Wayne A, Roberts IA, Dinndorf P, Brandalise S, Sanders JE, Matthews DC, Appelbaum FR, Storb R, Sullivan KM. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 1996 May;2(2):100-4.
41. French JA 2nd, Kenny D, Scott JP, Hoffmann RG, Wood JD, Hudetz AG, Hillery CA. Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood. 1997 Jun 15;89(12):4591-9.
42. Walters MC, Patience M, Leisenring W, Rogers ZR, Dinndorf P, Davies SC, Roberts IA, Yeager A, Kurtzberg J, Bunin N, Scott JP, Wall DA, Wayne AS, Wiley J, Darbyshire PJ, Mentzer WC, Smith FO, Sullivan KM. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant. 1997 Dec;3(6):310-5.
43. Scott JP 3rd, Scott JP 2nd, Chao YL, Newman PJ, Ward CM. A frameshift mutation at Gly975 in the transmembrane domain of GPIIb prevents GPIIb-IIIa expression--analysis of two novel mutations in a kindred with type I glanzmann thrombasthenia. Thromb Haemost. 1998 Oct;80(4):546-50.
44. Hillery CA, Scott JP, Du MC. The carboxy-terminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion. Blood. 1999 Jul 01;94(1):302-9.
45. Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, Buchanan GE, Rogers ZR, Dinndorf P, Davies SC, Roberts IA, Dickerhoff R, Yeager AM, Hsu L, Kurtzberg J, Ohene-Frempong K, Bunin N, Bernaudin F, Wong WY, Scott JP, Margolis D, Vichinsky E, Wall DA, Wayne AS, Pegelow C, Redding-Lallinger R, Wiley J, Klemperer M, Mentzer WC, Smith FO, Sullivan KM. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000 Mar 15;95(6):1918-24.
46. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol. 2000 May;109(2):322-7.
47. Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. Bleeding disorders: A common cause of menorrhagia in adolescents. J Pediatr. 2001 Jun;138(6):856-61.
48. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001 Dec;139(6):790-6.
49. Scothorn DJ, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W, Sarniak I, Fallon R, Chu JY, Pegelow CH, Wang W, Casella JF, Resar LS, Berman B, Adamkiewicz T, Hsu LL, Ohene-Frempong K, Smith-Whitley K, Mahoney D, Scott JP, Woods GM, Watanabe M, Debaun MR. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002 Mar;140(3):348-54.
50. Morrell DS, Pepping MA, Scott JP, Esterly NB, Drolet BA. Cutaneous manifestations of hemophagocytic lymphohistiocytosis. Arch Dermatol. 2002 Sep;138(9):1208-12.
51. Watkins NA, Du LM, Scott JP, Ouwehand WH, Hillery CA. Single-chain antibody fragments derived from a human synthetic phage-display library bind thrombospondin and inhibit sickle cell adhesion. Blood. 2003 Jul 15;102(2):718-24.
52. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003 Jun;111(6 Pt 1):e661-5.
53. Greenbaum LA, Kerlin BA, Van Why S, Punzalan RC, Trost BA, Pan CG, Scott JP. Concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemia. Pediatr Nephrol. 2003 Dec;18(12):1301-3.
54. Melzer-Lange MD, Walsh-Kelly CM, Lea G, Hillery CA, Scott JP. Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatr Emerg Care. 2004 Jan;20(1):2-4.
55. Panepinto JA, O'Mahar KM, DeBaun MR, Rennie KM, Scott JP. Validity of the child health questionnaire for use in children with sickle cell disease. J Pediatr Hematol Oncol. 2004 Sep;26(9):574-8.
56. Brousseau DC, Scott JP, Hillery CA, Panepinto JA. The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Acad Emerg Med. 2004 Sep;11(9):968-72.
57. Panepinto JA, Brousseau DC, Hillery CA, Scott JP. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2005 Feb;44(2):182-6.
58. Panepinto JA, O'Mahar KM, DeBaun MR, Loberiza FR, Scott JP. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol. 2005 Aug;130(3):437-44.
59. Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005 Oct 01;106(7):2269-75. PMCID: PMC1895275
60. Duke RL, Scott JP, Panepinto JA, Flanary VA. Perioperative management of sickle cell disease children undergoing adenotonsillectomy. Otolaryngol Head Neck Surg. 2006 Mar;134(3):370-3.
61. Hulbert ML, Scothorn DJ, Panepinto JA, Scott JP, Buchanan GR, Sarnaik S, Fallon R, Chu JY, Wang W, Casella JF, Resar L, Berman B, Adamkiewicz T, Hsu LL, Smith-Whitley K, Mahoney D, Woods G, Watanabe M, DeBaun MR. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J Pediatr. 2006 Nov;149(5):710-2.
62. Eggleston B, Patience M, Edwards S, Adamkiewicz T, Buchanan GR, Davies SC, Dickerhoff R, Donfield S, Feig SA, Giller RH, Haight A, Horan J, Hsu LL, Kamani N, Lane P, Levine JE, Margolis D, Moore TB, Ohene-Frempong K, Redding-Lallinger R, Roberts IA, Rogers ZR, Sanders JE, Scott JP, Sleight B, Thompson AA, Sullivan KM, Walters MC, Multicenter Study of HCT for SCA. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. Br J Haematol. 2007 Feb;136(4):673-6.
63. Chang Milbauer L, Wei P, Enenstein J, Jiang A, Hillery CA, Scott JP, Nelson SC, Bodempudi V, Topper JN, Yang RB, Hirsch B, Pan W, Hebbel RP. Genetic endothelial systems biology of sickle stroke risk. Blood. 2008 Apr 01;111(7):3872-9. PMCID: PMC2275038
64. Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost. 2009 Nov;7(11):1832-9. PMCID: PMC3825106
65. Walters MC, Hardy K, Edwards S, Adamkiewicz T, Barkovich J, Bernaudin F, Buchanan GR, Bunin N, Dickerhoff R, Giller R, Haut PR, Horan J, Hsu LL, Kamani N, Levine JE, Margolis D, Ohene-Frempong K, Patience M, Redding-Lallinger R, Roberts IA, Rogers ZR, Sanders JE, Scott JP, Sullivan KM, Multicenter Study of Bone Marrow Transplantation for Sickle Cell Disease. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010 Feb;16(2):263-72. PMCID: PMC2919571
66. Scott JP. Hydroxurea and sickle cell disease: Its been a long, long time coming. Pediatr Blood Cancer. 2010 Feb;54(2):185-6.
67. Buesing KL, Tracy ET, Kiernan C, Pastor AC, Cassidy LD, Scott JP, Ware RE, Davidoff AM, Rescorla FJ, Langer JC, Rice HE, Oldham KT. Partial splenectomy for hereditary spherocytosis: a multi-institutional review. J Pediatr Surg. 2011 Jan;46(1):178-83.
68. Ware RE, Schultz WH, Yovetich N, Mortier NA, Alvarez O, Hilliard L, Iyer RV, Miller ST, Rogers ZR, Scott JP, Waclawiw M, Helms RW. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer. 2011 Dec 01;57(6):1011-7. PMCID: PMC3171640
69. Collins CL, Scott JP, Panepinto JA, Punzalan RC. Severe thrombocytopenia in a child secondary to passive platelet antibody transfer from a plasma transfusion. J Pediatr Hematol Oncol. 2013 Jul;35(5):e226-8. PMCID: PMC4508016
70. Epping AS, Myrvik MP, Newby RF, Panepinto JA, Brandow AM, Scott JP. Academic attainment findings in children with sickle cell disease. J Sch Health. 2013 Aug;83(8):548-53.
71. Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE, Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH). Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013 Nov;88(11):932-8. PMCID: PMC4631259
72. Dobrozsi S, Flood VH, Panepinto J, Scott JP, Brandow A. Vitamin B12 deficiency: the great masquerader. Pediatr Blood Cancer. 2014 Apr;61(4):753-5.
73. Niebler RA, Mitchell ME, Scott JP. Repeated aortopulmonary shunt thrombosis in a neonatal patient with a low antithrombin level. World J Pediatr Congenit Heart Surg. 2014 Jan 01;5(1):94-6.
74. Badaki-Makun O, Scott JP, Panepinto JA, Casper TC, Hillery CA, Dean JM, Brousseau DC, Pediatric Emergency Care Applied Research Network (PECARN) Magnesium in Sickle Cell Crisis (MAGiC) Study Group. Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial. Pediatr Blood Cancer. 2014 Jun;61(6):1049-54. PMCID: PMC3995128
75. Rice HE, Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Smithers C, Brown RL, Kalfa T, Langer JC, Cada M, Oldham KT, Scott JP, St Peter S, Sharma M, Davidoff AM, Nottage K, Bernabe K, Wilson DB, Dutta S, Glader B, Crary SE, Dassinger MS, Dunbar L, Islam S, Kumar M, Rescorla F, Bruch S, Campbell A, Austin M, Sidonio R, Blakely ML, Splenectomy in Congenital Hemolytic Anemia (SICHA) Consortium. Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry. Am J Hematol. 2015 Mar;90(3):187-92. PMCID: PMC4333061
76. Brousseau DC, Scott JP, Badaki-Makun O, Darbari DS, Chumpitazi CE, Airewele GE, Ellison AM, Smith-Whitley K, Mahajan P, Sarnaik SA, Casper TC, Cook LJ, Dean JM, Leonard J, Hulbert ML, Powell EC, Liem RI, Hickey R, Krishnamurti L, Hillery CA, Nimmer M, Panepinto JA, Pediatric Emergency Care Applied Research Network (PECARN). A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood. 2015 Oct 01;126(14):1651-7. PMCID: PMC4591790
77. Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Jason Smithers C, Brown RL, Kalfa T, Langer JC, Cada M, Oldham KT, Scott JP, St Peter SD, Sharma M, Davidoff AM, Nottage K, Bernabe K, Wilson DB, Dutta S, Glader B, Crary SE, Dassinger MS, Dunbar L, Islam S, Kumar M, Rescorla F, Bruch S, Campbell A, Austin M, Sidonio R, Blakely ML, Rice HE, Splenectomy in Congenital Hemolytic Anemia Consortium. Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. J Pediatr Surg. 2016 Jan;51(1):122-7. PMCID: PMC5083068
78. Brandow AM, Nimmer M, Simmons T, Charles Casper T, Cook LJ, Chumpitazi CE, Paul Scott J, Panepinto JA, Brousseau DC. Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease. Am J Hematol. 2016 12;91(12):1175-1180.
79. Cancio MI, Aygun B, Chui DHK, Rothman JA, Scott JP, Estepp JH, Hankins JS. The clinical severity of hemoglobin S/Black (<sup>A</sup> γδβ)<sup>0</sup> -thalassemia. Pediatr Blood Cancer. 2017 Nov;64(11). PMCID: PMC6615052
80. Hulbert ML, Panepinto JA, Scott JP, Liem RI, Cook LJ, Simmons T, Brousseau DC, Pediatric Emergency Care and Research Network Sickle Cell Disease Working Group. Red blood cell transfusions during sickle cell anemia vaso-occlusive crises: a report from the magnesium in crisis (MAGiC) study. Transfusion. 2017 08;57(8):1891-1897.
81. Acquazzino MA, Miller M, Myrvik M, Newby R, Scott JP. Attention Deficit Hyperactivity Disorder in Children With Sickle Cell Disease Referred for an Evaluation. J Pediatr Hematol Oncol. 2017 07;39(5):350-354.
82. Cancio MI, Aygun B, Chui DHK, Rothman JA, Scott JP, Estepp JH, Hankins JS. The clinical severity of hemoglobin S/Black (<sup>A</sup> γδβ)<sup>0</sup> -thalassemia. Pediatr Blood Cancer. 2017 Nov;64(11). PMCID: PMC6615052
83. Niebler RA, Woods KJ, Murkowski K, Ghanayem NS, Hoffman G, Mitchell ME, Punzalan RC, Scott JP, Simpson P, Tweddell JS. A Pilot Study of Antithrombin Replacement Prior to Cardiopulmonary Bypass in Neonates. Artif Organs. 2016 Jan;40(1):80-5.
84. Morrison AK, Myrvik MP, Brousseau DC, Drendel AL, Scott JP, Visotcky A, Panepinto JA. Parents' pain medication underdosing is associated with more emergency department visits in sickle cell disease. Pediatr Blood Cancer. 2018 04;65(4). PMCID: PMC5821544
85. Voulgarelis S, Vitola B, Lerret SM, Hong JC, Scott JP. Perioperative anticoagulation practices for pediatric liver transplantation. Pediatr Transplant. 2018 06;22(4):e13193.
86. Newby RF, Epping A, Geiger JA, Miller MS, Scott JP. Visual Motor Integration in Children With Sickle Cell Disease. J Pediatr Hematol Oncol. 2018 10;40(7):495-498.
87. Flood VH, Scott JP. Bleeding and Thrombosis Nelson Pediatric Symptom-Based Diagnosis. 24 April 2017:682-701.
88. Zwifelhofer NMJ, Bercovitz RS, Cole R, Yan K, Simpson PM, Moroi A, Newman PJ, Niebler RA, Scott JP, Stuth EAD, Woods RK, Benson DW, Newman DK. Platelet Function Changes during Neonatal Cardiopulmonary Bypass Surgery: Mechanistic Basis and Lack of Correlation with Excessive Bleeding. Thromb Haemost. 2020 Jan;120(1):94-106. PMCID: PMC7003188
89. Zwifelhofer NMJ, Bercovitz RS, Cole R, Yan K, Simpson PM, Moroi A, Newman PJ, Niebler RA, Scott JP, Stuth EAD, Woods RK, Benson DW, Newman DK. Platelet Function Changes during Neonatal Cardiopulmonary Bypass Surgery: Mechanistic Basis and Lack of Correlation with Excessive Bleeding. Thromb Haemost. 2020 Jan;120(1):94-106. PMCID: PMC7003188
90. Meier ER, Creary SE, Heeney MM, Dong M, Appiah-Kubi AO, Nelson SC, Niss O, Piccone C, Quarmyne MO, Quinn CT, Saving KL, Scott JP, Talati R, Latham TS, Pfeiffer A, Shook LM, Vinks AA, Lane A, McGann PT. Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia. Trials. 2020 Nov 27;21(1):983. PMCID: PMC7691962
91. Singh A, Danda V, Van Swol L, Scott JP, Brandow AM, Panepinto JA. Recommendation to reality: Closing the transcranial Doppler screening gap for children with sickle cell anemia. Pediatr Blood Cancer. 2021 Feb;68(2):e28831.
 
Books, Chapters, and Reviews
1. Montgomery RR, Kawai Y, Scott JP: Homologous functions and interactions of platelets and endothelial cells. Platelet Irnmunobiology. TJ Kunicki , JN George (eds), J.B. Lippincott Company, Philadelphia, 1989.
2. Gill JC, Thometz J, Scott JP, Montgomery RR: Musculoskeletal problems in hemophilia: Hemophilia in the Child and Adult, M Hilgartner, C Pochedly eds., Raven Press, 1989.
3. Montgomery RR and Scott JP: Diseases of Coagulation: The Fluid Phase in Hematology of Infancy and Childhood. DG Nathan and FA Oski eds., 4th edition, 1993.
4. Montgomery RR, Gill JC, Scott JP: Hemophilia and von Willebrand Disease. In: Hematology of Infancy and Childhood. Nathan, Orkin, Oski, Eds., WB Saunders, Philadelphia, PA, 1998.
5. Scott, JP: Hematology in Nelson's Essentials of Pediatrics, RE Behrman and RM Kliegman eds., WB Saunders, Philadelphia, 4th edition, 2001.
6. Scott JP: Bleeding and Thrombosis in Practical Strategies in Pediatric Diagnosis and Therapy, RM Kliegman, ML Nieder, DM Super, eds. WB Saunders, Philadelphia, 2001.
7. Montgomery RR, Scott JP: Hemorrhage and Thrombotic Diseases in Nelson Textbook of Pediatrics, Behrman RE, Kliegman RM, and Jenson HB eds., WB Saunders, Orlando, FL, 2002.
8. Montgomery RR, Gill JC, Scott JP: Chapter 41, Hemophilia and von Willlebrand Disease in Hematology oflnfancy and Childhood, 6th Edition. Nathan DG, Orkin SH, Ginsburg D, Look AT, Saunders WB eds., Philadelphia, pp. 1547-1576, 2003.
9. Scott JP and Zieger B: Pediatric Hematology in Clinical Hematology. Young NS, Gerson, SL and High KA eds., Elsevier, Philadelphia, pp. 927-943, 2006.
10. Montgomery RR, Scott JP: Hemorrhage and Thrombotic Diseases in Nelson Textbook of Pediatrics 17th edition, Behrman RE, Kliegman RM, and Jenson HB eds., WB Saunders, Orlando, FL, pp.1651-1674, 2004.
11. Scott JP: Hematology in Nelson's Essentials of Pediatrics, RM Kliegman, Marcdante K, Jenson Hand Behrman RE eds., WB Saunders, Philadelphia, 5th edition, 2006.
12. Scott JP: Hematology in Nelson's Essentials of Pediatrics, RM Kliegman, Marcdante K, Jenson Hand Behrman RE eds., WB Saunders, Philadelphia, 6th edition, 2011.
13. Scott JP, Raffini L, Montgomery RR: Hemorrhage and Thrombotic Diseases in Nelson Textbook of Pediatrics 19th edition, Behrman RE, Kliegman RM, and Jenson HB eds., 2011
14. Scott JP, Raffmi L, Flood V: Hemorrhage and Thrombotic Diseases in Nelson Textbook of Pediatrics 20th edition, Behrman RE, Kliegman RM, and Jenson HB eds. 2014
15. Scott JP: Hematology in Nelson's Essentials of Pediatrics, RM Klieg:man, Marcdante K, Jenson Hand Behrman RE eds., WB Saunders, Philadelphia, 7th edition, 4/2014.
16. Scott JP, Raffini L, Flood V: Hemorrhagic and Thrombotic Diseases in Nelson Textbook of Pediatrics 21st edition, Behrman RE, Kliegman RM, and Jenson HB eds. 2019
 
Editorials, Letters to Editor, Other
1. Wedin SL, Scott JP. Is biliary sludge a stone-in-waiting? Journal of Pediatrics. 129(3):321-2, 1996.
2. Scott JP. "It's Been A Long, Long Time Comin'!" Pediatric Blood Cancer. 10.1002. 0734(22340), 2009.
 
Abstracts
1. Scott JP, Montgomery RR: Platelet von Willebrand's antigen II (v WAG II) active release by aggregating agents and its study in vivo. Blood 54: 260a, 1979.
2. Scott JP, Johnson JW, Montgomery RR: In vitro and in vivo studies on a new platelet release protein - v WAG II. Clin Res 28:323a, 1980.
3. Scott JP, Labotka RJ, Kramer C: Acquired von Willebrand 's syndrome in association with therapy of acute lymphoblastic leukemia. Blood 65(5) Supp 1:204a, November 1982.
4. Scott JP, Morgan ER: Coagulopathy of metastatic neuroblastoma (NBL). Blood 69(5) Supp 1:222a, November 1982.
5. Scott JP, McLeod B: Infusion studies of single donor cryoprecipitate obtained from plasma exchange donation. Blood 60(5) Supp 1:182a, 1982.
6. Gerber PS, Martin C, Scott JP, Pachman LM: Studies of thrombocytosis and coagulation parameters in active juvenile rheumatoid arthritis (JRA). Clin Research 30(4):799a, 1982.
7. Scott JP, McLeod C: Infusion studies of a single donor factor VIII obtained from plasm a exchange donation. Clin Research 31:323a, 1983.(Presented - American Federation for Clinical Research, May 2, 1983, Washington, D.C.).
8. Scott JP, Pachman LM, Gerber PS, Maryjowski MC, et al.: Activation of coagulation in systemic JRA (S-JRA). Arthritis Rheum 26:557a,1983.
9. Pachman LM, Scott JP, Arroyave CM, Maryjowski MC: Juvenile derma-tomyositis (JDMS): Activation of coagulation and complement systems. Clin Res 31 :796a. (Presented - Central Society for Clinical Research, November 5, 1983).
10. Scott JP, Arroyave C, Maryjowski M, Gerber P, Pachman LM: Intravascular coagulation and complement activation in systemic onset juvenile arthritis. Pediatr Res 18:913a. (Presented - SPR, San Francisco, California, May 1984)
11. Pachman LM, Christensen JL, Scott JP, Arroyave CM, Friedrnand JM, Maryjowski MC: Active juvenile dermatomyositis is associated with complement and coagulation activation, increased titers to antinuclear antibody and coxsackie B viral antigens. Pediatr Res 18:998a, 1984(Presented - SPR, May 3, 1984)
12. McLeod BC, Cole ER , Sassetti RJ, Scott JP: Desmopressin augmentation of factor VIII yields in plasma exchange donation of cryoprecipitate. (Abstract 394A) Clinical Research, Volume 33, Number 2, 1985. (Presented - American Federation for Clinical Research in Washington, D.C.)
13. Scott JP, Emrich R, Morgan E: Procoagulation(PC)and plasminogen activator(PA)function of childhood leukemic blasts. Pediatr Res 19:265a, 1985. (Presented - SPR in Washington, D.C., May 1985).
14. Vailas GN, Scott JP, Brouillette RT, Shkolnick A, Conway J, Wiringa K: Newer diagnostic modalities and therapy for a neonatal aortic thrombosis. Pediatr Res 19:368a, 1985.
15. Scott JP, Cole ER, Sassetti RJ, McLeod BC. DDAVP augments factor VIII yields from plasma exchange donation of cryoprecipitate. Hemostasis Thrombos 54:265a, 1985(Presented - 10th International Congress on Thrombosis and Haemostasis , San Diego
16. Scott JP, Joseph E, Morgan ER: Relationship of blast cell procoagulant (PC) and plasminogen activator (PA) production of coagulopathy in childhood acute leukemia. Blood 66:327a, 1985.
17. Green D, Scott JP: Fibrinopeptide A and protein C in sickle cell disease. Blood 66:321a,1985.
18. Scott JP, Zumwalt KL, Montgomery RR: Ristocetin binds von Willebrand factor in a dose dependent manner that is not inhibited by monoclona l or polyclonal antibodies. Blood 70:1433a, 1987(Presented ASH,1987)
19. Scott JP, Montgomery RR, Zumwalt KL: A rapid von Willebrand factor (vWf) binding technique that distinguishes Type liB from platelet-type von Willebrand's disease (vWd). Clin. Res. 36:418a, 1988. (Presented-American Federation for Clinical Research, April 29, 1988)
20. Scott JP, McGann K, Gill JC, McLeod BC, Gamerman S: Is immune function altered by infusion of high protein load materials in the treatment of hemophilia A? Pediatr. Res. 23:347a, 1988. (Presented - SPR, May 5, 1987)
21. Scott JP, Levine S, Endres-Brook J, Gill JC, Montgomery RR: Unlike von Willebrand factor (vWf) levels, ristocetin-induced vWf binding to platelets is unaffected by blood type. Blood 72:31Oa, 1988. (Presented - ASH, December 1988)
22. Menitove JE, Gill JC, Scott JP, Ottum M, Montgomery RR: Hemophilic patients treated with lyophilized Factor VIII concentrates are seronegative for HTLV-I antibody. Blood 72:282a, 1988.
23. Montgomery RR, Vokac EA, Scott JP, Reynolds ER, Rosen NL, Newman PJ, Friedm an KD: Does von Willebrand factor bind to endothelial cells through a GPlb-like receptor? Blood 72:333a, 1988.
24. McGann KA, McLeod BC, Gill JC, Gamerman SA, Scott JP: Long-term immunologic follow-up ofhemophiliac patients treated with cryoprecipitate (CP) from D-DAVP stimulated plasma exchange donation (S-PED) Blood 74:101a, 1989
25. Montgomery RR, Rayner JC, Simon K, Saskowski J, Gill JC, Scott JP, Vokac E: Plasm a pro-von Willebrand factor: an indicator of in vivo endothelial cell destruction. Blood 74:132a, 1989.
26. Rayner JC, Gill JC, Scott JP, Montgomery RR: The genetic evaluation of the vWf gene using the polymerase chain reaction. Transfusion 30:3, 1990.
27. McLeod BC, Kisker T, Hasegawa D, Edson R, Gamerman S, Scott JP: Incidence of inhibitors in hemophiliacs treated with single-donor cryoprecipitate from plasma exchange donation. Blood 74:37a, 1989.
28. Schmidt ML, Smith, HE, Garnerman S, Glaser S, Scott JP: Prolonged recombinant activated factor VII(rFVIIa) treatment for severe bleeding and surgical hemostasis in a factor IX­ deficient patient with an inhibitor. (Presented- APS/SPR, 1990).
29. Gill JC, Menitove JE, Scott JP, Montgomery RR: Prevalence of antibody to hepatitis C in recipients of coagulation factor replacement therapy. Blood 76:3991, 1990.
30. Scott JP, Montgomery RR, Retzinger GS: Dimeric ristocetin mediates von Willebrand factor (vWf)dependent platelet agglutination. Blood 76:438a, 1990.
31. Scott JP, Montgomery RR, O'Hair D, Raisleger P, Pollnow S, McManus R: Anti-endothelial cell antibodies in concordant cardiac xenograft rejection. Pediatr Res 1991. (Presented - SPR, New Orleans, LA, May 3, 1991)
32. Neahring BJ, Scott JP, Visentin GP, Gottschall JL, Aster RH: Anti-endothelial cell antibodies in plasma of patients with quinine-induced hemolytic-uremic syndrome. Blood 10:52a, 1992. (Presented - ASH, Anaheim, CA, December 5, 1992)
33. Rock AR, Gill JC, Scott JP: The successful treatment of a child with refractory autoimmune pancytopenia using a protein A-immunosorption column. Blood 10:877a, 1992. (Presented-ASH, Anaheim , CA, December 7, 1992
34. Scott JP, Hatton J, Rock AR, Knopp J, Gill JC, Montgomery RR: The differential effect of ABO blood type on von Willebrand factor (vWF) levels in plasma, platelets, and in plasma following DDAVP administration. Blood 10:364a, 1992 (Presented - ASH, Anaheim, CA, December 8, 1992)
35. Liu X, Scott JP, Mancuso DJ, Kroner PA, Newman PJ, Vokac EA, Montgomery RR : Substitution of Pro or Glu for Arg 478 of von Willebrand factor (vWf) preferentially affects vWf interachon with platelets. Blood 10:368a, 1992 (Presented - ASH, Anaheim, CA, December 8, 1992)
36. Scott JP, Tsao A, P Raisleger, D O'Hair, R McManus: Anti-endothelial cell antibody-antigen systems in concordant cardiac xenograft transplant rejection. Circulation 86:1-627, 1992 (Presented - AHA, New Orleans, November 18, 1992)
37. Montgomery RR, Rock A, Gill JC, Scott JP, KiuessendorfM, Baxter-Lowe LA: Detection of type I von Willebrand disease by automated VNTR analysis. Clin Research 41:275a, 1993. (Presented -SPR/AFCR, May 3, 1993, Washington, DC)
38. Scott JP, Robinson E, Hillery CA, Misiewicz V, Labotka RJ : A pilot study of hydroxyurea therapy of severely affected children with Sickle Cell Disease (SCD). Clin Res 41:313a, 1993. (Presented -SPR/AFCR, May 3, 1993, Washington, DC)
39. Scott JP, Gill JC, Rock A, Levine S, Vokac EA, Montgomery RR: The effect of ABO type on the synthesis, release, and platelet binding of von Willebrand factor (vWf). Thromb Hemost 69:946a, 1993. (Presented- ISTH, July 6, 1993, New York, NY)
40. Gedeit RG, Wendelberger KJ, Scott JP: Heparin-induced tumor necrosis factor inhibition during cardiopulmonary bypass. Thromb Hemost 69:1015a, 1993.(Presented - ISTH July 8, 1993, New York, NY)
41. Scott JP, Vokac E, Foster PA, Kassay K, and Montgomery RR: The von Willebrand factor propolypept ide (vWAgll) as a marker of acquired von Willebrand syndrome. Blood 82:150a, 1993. (Presented -ASH, Dec 5, 1993, St. Louis, MO).
42. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies associated with heparin-induced thrombocytopenia and thrombosis recognize platelet factor 4 bound to heparin or endothelial cell glycosaminoglycans. Blood 82:162a, 1993. (Presented- ASH, Dec 5, 1993, St. Louis, MO)
43. Scott JP, Misiewicz VM, Robinson E, Hillery CA, Labotka, RJ: Hydroxyurea therapy of severely affected children with sickle cell disease. (Presented - 19th Meeting of National Sickle Cell Program, March 24, 1994)
44. Montgomery RR, Scott JP, Kroner PA, Abel ML, Vokac EA, Fahs SA, Gill JC, Kawai Y: A naturally occurring mutation of the vWF propolypeptide, vW Agll, prevents vWF N­ terminal multimerization, FVIII-binding and collagen-binding but not vWF binding to platelet GPib. XVth Congress of the International Society on Thrombosis and Haemostasis. Jerusalem, Isreal, June 11-16, 1995
45. Hillery CA, Du MC, Barbour TJ, Montgomery RR, Scott, JP: An acidic lipid purified from sickle red blood cells specifically binds to thrombospondin. Blood 84:1609a, 1995
46. Scott JP, Misiewicz VM, Robinson E, Hillery CA, Labotka RJ: Long term follow-up of severely affected children with Sickle Cell Disease (SCD) treated with Hydroxyurea (HDU). (Presented - 20th Meeting of the National Sickle Cell Program, March 20, 1995)
47. Hillery CA, Du MC, Barbour TJ, Scott JP: Potential role for sulfated glycolipids in the adhesion of sickle red blood cells to thrombospondin. (Presented-20th Meeting of the National Sickle Cell Program, March 24, 1995)
48. French JA, Hudetz AG, Wood JD, Scott JP, Kampine JP, Kenny D, Hi llery CA: Enhanced adhesion of sickle red blood cells to rat brain microvasculature: an in vivo model. 20th Meeting of the National Sickle Cell Program, March 24, 1995
49. French JA, Hudetz AG , Kenny D, Du MC, Kampine JP, Scott JP, Hillery CA: Sickle erythrocytes decrease cerebral blood flow in rats when nitric oxide synthesis is inhibited. Blood 84:556a, 1995
50. Rosenberg JB, Kroner PA, Scott JP, Gill JC, Foster PA, Kawai Y, Abel M, Vokac EA, Fahs S, Montgomery RR: A point mutation in the D1 Domain of Von willebrand Factor results in defective collagen and factor VIII binding but not platelet GPIb binding or release from AtT-20 cells. Blood 84: 1781a, 1995
51. Du MC, Scott JP, Hillery CA: Red blood cells treated with phenylhydrazine or calcium ionophore have increased adhesion to thrombospondin, similar to sickle erythrocytes. Blood 84:537a, 1995
52. Scott JP, Vokac EA, Schroeder T, Foster PA, Gill JC, Montgomery RR: The von Willebrand factor propolypeptide, von Willebrand antigen II (vWAgII), distinguishes acquired von Willebrand factor (vWF) from AvWS due to increased clearance of vWF. Blood 86:773a, 1995
53. Scott JP, Schroder T, Rosenberg J, Montgomery RR: Recombinant 2B von Willebrand factor (2BVWF) shows increased binding to platelelts in fluid phase but does not induce increased binding of formalin-fixed washed platelets (FFWP) to Type III collagen at high shear. (SPR Annual Meeting, Washington, D.C., May 6-10 1996)
54. Hillery CA, Du CA, French II JA, Scott JP: Sickle red blood cells bind to the 140 kDa C­ terminal domain ofthrombospondin. (SPR Annual Meetin g, Washington, D.C., May 6-10, 1996)
55. French II JA, Hudetz AG, Kenny D, Du MC, Kampine JP, Scott JP, Hillery CA: Nitric oxide synthase inhibition decreases cerebral blood flow in rats infused with sickle erythrocytes. (SPR Annual Meeting, Washington DC, May 6-10,1 996)
56. Punzalan RC, Du MC, Low PS, Scott JP, Hillery CA: Role ofhydration status in erythrocyte adhesion to thrombospondin (Presented-ASH, San Diego, CA December 5-9, 1997)
57. Melzer-Lange MD, Walsh-Kelly CM, Lea G, Hillery CA, Scott JP: Initiation of patient controlled analgesia infusions for sickle cell pain crisis in a pediatric emergency department.(APA Annual Meeting, New Orleans, LA, May 1-5, 1998)
58. Osbourne SE, Johnson ST, Scott JP, Hillery CA, Gottschall JG: A simple and effective protocol to reduce red cell alloimmunization among patients with sickle cell disease.(AABB meeting, 1998)
59. Scott JP, Gill JC, Vokac EA, Friedman KD, and Montgomery RR: von Willebrand antigen II (vWAgll) distinguishes acquired von Willebrand syndrome (AvWS) due to decreased synthesis from that due to increased clearance ofvWF. Pediatric Research 1998: vol. 43, issue 4, part 2, pg 138a
60. Montgomery RR, Endres JL, Rosenberg JB, Scott JP, and Cox Gill J: Creating a DDAVP releasable pool of factor Vlll: its impact on the gene therapy of hemophilia. Pediatric Research 1998: vol. 43, issue 4, part 2, pg 136a
61. Du MC, Watkins NA, Scott JP, Ouwehand WH, Hillery CA: Single chain antibody fragments derived from a human synthetic phage display library bind the cell binding domain of thrombospondin and inhibit sickle cell adhesion. (Presented - ASH, Miami, FL, December 4-8, 1998)
62. Hillery CA, Punzalan RC, Trost BA, Scott JP, Hudetz AG: Chondoitin sulfate-A limits cerebral ischemia in sickle erythrocyte- infused rates. (Presented - National Sickle Cell Program, San Francisco, March 8, 1999)
63. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE: A two-year pilot trial of hydroxyurea (HU) in very young children with sickle cell disease (SCD) (ASH, New Orleans, LA, December 3-7, 1999)
64. Scott JP, Johnson ST, Curtis BR, Gottschall JL: IgA-mediated autoimmune hemolytic anemia (AIHA) detected by flow cytometry and successful therapy with cyclosporin A(CsA). (ASH, New Orleans, LA, December 3-7, 1999)
65. Hillery CA, Du MC, Scott JP, Ware RE, Rogers ZR, Wynn LW, Wang WC: Red blood cell adhesion remains low in very young children with sickle cell disease receiving hydroxyurea therapy. (ASH, New Orleans, LA, December 3-7, 1999)
66. Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP: Bleeding disorders are common cause of adolescent menorrhagia. (Presented - PAS/AAP Joint Meeting, Boston, MA, May 12-15, 2000)
67. Talano JM, Johnson S, Gottschall JL, Curtis BR, Scott JP: lgA-Mediated autoimmune hemolytic anemia (AIHA) detected by flow cytometry (FC) responsive to cyclosporin (CsA) therapy.(Presented- PAS/AAP Joint Meeting, Boston, MA, May 12-15, 2000)
68. Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP: Bleeding disorders are common cause of adolescent menorrhagia(Presented- ASPHO, Minneapolis, MN, September 14-16, 2000)
69. Talano JM, Gottschall JL, Johnson ST, Pugh TM, Hillery CA, Scott JP: Partial phenotype matching (Rh, Kell) reduces alloirnrnun ization in children with Sickle Cell Disease (SCD). (Presented- ASPH0, Minneapolis, MN, September 14-16, 2000)
70. Kerlin BA, Greenbaum LA, Punzalan RC, Trost BA, Pan CG, Gill JC, Sheth KJ, Scott JP: Concurrent post-infections glomerulonephritis and anti-I hemolytic anemia. (Presented­ ASPHO, Minneapolis, MN, September 14-16, 2000)
71. Brosig C, Kratoska B, Olson J, Nocton J, Montavon B, Davies H, Uilein J, Immel K, Scott JP: Effects of dismissed pain reports in children with juvenile rheumatoid arthritis (JRA). (Submitted-VII European Pediatric Rheumatology Congress, Geneva, Switzerland, September 23-27, 2000)
72. Du MC, Holzman SL, Mohandas N, Trost BA, Scott JP, Hillery CA: Increased fibrin deposition at sites of vaso-occlusion in transgenic sickle mice (ASH, San Francisco, CA, December 1-5, 2000)
73. Holzman SL, Hui S, Lily MD, Mohandas N, Scott JP, Hudetz AG, Hillery CA: Inhibition of nitric oxide synthase induces acute vase-occlusion in transgenic sickle mice. (Presented - ASH, San Francisco, CA, December 1-5, 2000)
74. Kerlin BA, Scott JP: Recombinant erythropoietin and corticosteroid therapy for delayed hemolytic transfusion reactions in hemoglobin SS disease. (Presented - PAS Annual Meeting, Baltimore, MD, April 28-May 1, 2001)
75. Talano JA, Hillery CA, Gottschall JL, Baylerian, Scott JP: Delayed hemolytic transfusion reactions (DHTR) in sickle cell disease (SCD) (Presented - PAS Annual Meeting, Baltimore, MD, April 28 - May 1, 2001)
76. Friedman KD, Luhm RA, Scott JP, Maloney KW, Wetzel N, Endres J, Montogrnery RR: Factitious Diagnosis of Type 2M von Willebrand Disease (VWD) with a Mutation in von Willebrand factor (VWF) that affects the Ristocetin Cofactor Assay but Does Not Significantly Affect VWF Function In Vivo. (Poster Presentation- ASH, Orlando, FL, December 7-11, 2001)
77. Wandersee NJ, Sillah NM, Watkins NA, Scott JP, Ouwehand WH, Hillery CH: Single Chain Antibody Fragments Derived From A Human Phage Display Library Preferentially Bind Sickle Red Blood Cells And Inhibit Sickle Cell Adhesion. (Poster Presentation-ASH, Orlando, FL, December 7-11, 2001)
78. Rogers ZR, Ware RE, Wynn LW, Scott JP, Lane PA, Wang WC: Safety And Hematologic Efficacy Of Four Years Of Hydroxyurea (HU) Therapy For Very Young Children With Sickle Cell Anemia (SCA): The HUSOFT Extension Study. (Poster Presentation-ASH, Orlando, FL, December 7-11, 2001)
79. Browning MB, Baylerian DM, Johnson ST, Scott JP, Gottschall JL: Positive Direct Antiglobulin Tests In A Pediatric Population. (Poster Presentation - ASH, Orlando, FL, December 7-11, 2001)
80. Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Johnson ST, Scott JP: Delayed Hemolytic Transfusion Reactions (DHTR) in Children with Sickle Cell Disease (SCD). (Submitted -ASH, Orlando, FL, December 7-11, 2001)
81. Panepinto JA, Lethert K, Scott JP, Gill JC: Children with a Mild Platelet Function Defect: Clinical Symptoms and Their Relationship to Coagulation Studies. (Poster Presentation - 2002 PAS Annual Meeting, Baltimore, MD, May 4-7, 2002)
82. Morrell DS, Pepping MA, Scott JP, Esterly NB, Drolet BA: Cutaneous manifestations of hemojphagocytic lymphohistiocytosis. Arch Dermatol, 138: 1208-112, September 2002
83. Hillery CA, Sillah NM, Wandersee NJ, Holzman SL, Gavazova S, Foster T, Scott JP, Montgomery RR, Saunthararajah Y, DeSimone J. Effect of Fetal Hemoglobin Induction by Decitabine in Erythrocyte Adhesion, Coagulation Parameters and Markers of inflammation in Patients with Sickle Cell Disease. (ASH presentation, Philadelphia, PA, December 8, 2002)
84. Stefana Gavazova, Joan C. Gill, J. Paul Scott, Cheryl A. Hillery, Kenneth D. Friedman, Nadine Wetzel, Mary Jozwiak, Sandra L. Haberichter, Pamela Christopherson, Robert R. Montgomery: A Mutation in the D4 Domain ofVon Willebrand Factor (VWF) Results in a Variant ofType 1 Von Willebrand Disease with Accelerated InVivo VWF Clearance. (ASH Presentation, Philadelphia, PA, December 9, 2002)
85. Panepinto JA, Hillery CA, Scott JP. Seasonal Variation in Hospital Length of Stay in Children with Sickle Cell Disease. (ASH presentation, Philadelphia, PA, December 9, 2002)
86. Talano JM, Johnson ST, Friedman KD, Ilstrup SJ, Curtis BR, Scott JP, Gottschall JM. Serologic Characteristics of Three Cases of IgA Mediated Autoimmune Hemolytic Anemia (AIHA) Confirmed by Flow Cytometry. Poster presentation.
87. Gavazova S, Gill JC, Scott JP, Hillery CA, Friedman KD, Wetzel NP , Haberichter SL, Montgomery RR: Assay of the VWF Propeptide in Patients with Type 1 von Willebrand Disease (VWD) and the Identification of Patients with a S2179F Mutation in the D4 Region of VWF. Oral Presentation, The International Society of Thrombosis and Haemostasis, 2003
88. Hillery CA, Foster TD, Holzhauer SL, Scott JP, Panepinto JA, Trost BA, Mohandas N, Degen JL, Wandersee NJ. Fibrinogen Deficiency Decreases Hepatic Infarction in a Stem Cell Transplant Model of Murine Sickle Cell Disease. Blood 102:a (Oral, ASH, San Diego, 2003)
89. Brousseau DC, Panepinto JA, Hillery CA, Scott JP. The effect of intravenous magnesium sulfate on length of stay for children hospitalized with sickle cell pain crises. Blood 102:a (Poster, American Society of Hematology, San Diego 2003)
90. Epping AS, Newby RF, Panepinto JA, Brandow AM, Jirovec, DL and Scott JP. Patterns of academic achievement in children with sickle cell disease. Pediatric Blood and Cancer, 52(6)703, presented American Society of Pediatric Hematology Oncology 2009
91. Epping AS, Newby RF, Panepinto JA, Brandow AM, and Scott JP. Sickle Cell Patients' Academic Patterns. Oral presentation at the Annual Meeting of the Interdisciplinary Pediatric Behavioral Health Research Conference, Wauwatosa, Wisconsin February 2009
92. Fields AD, Newby RF, Scott JP, Epping AS. Case Report: Cognitve deficits in a pediatric patient with SCD and chronic lead exposure. Oral presentation at the National Academy of Neuropsychology 29th Annual Meeting, New Orleans, Louisiana November, 2009
93. Epping AS, Jirovec DL, Newby RF, Panepinto JA, Brandow AM, Scott JP, Transitional care: Education and employment outcomes of adults with sickle cell disease. Oral presentation at the Annual Meeting of the Interdisciplinary Pediatric Behavioral Health Research Conference, Wauwatosa, Wisconsin, February 2010
94. Epping AS, Newby RF, Panepinto JA, Brandow AM, Jirovec DL, Scott JP. Transitional care: Education and employment outcomes of adults with sickle cell disease. Poster presented at the American Society of Pediatric Hematology/Oncology 23rd Annual Meeting, Montreal, Quebec, Canada, April 2010
95. Epping AS, Newby RF, Panepinto JA, Brandow AM, Jirovec DL, Scott JP. Attention deficit hyperactivity disorder and sickle cell disease. Oral presentation at the Sickle Cell Disease Association of American, 28th Annual Meeting, Washington DC, September 2010
96. Epping AS, Newby RF, Scott JP. Visual-motor integration difficulties in sickle cell disease. Oral presentation at the Cell Disease Research and Educational Symposium and Annual Scientific, 5th Annual Meeting, Hollywood FL, February 2011
97. Neahring B, Scott JP, Visentin GP, Gottschall J, Aster RH: Quinine-dependent anti­ endothelial cell antibodies in plasma of patients with hemolytic-uremic syndrome. Thromb Hemost 69:641a, 1993. (Presented- ISTH, July 3,1993, New York, NY)